OzUK: Pioneering Inhalation Solutions
With over three decades of dedicated experience in innovator product development, OzUK stands at the forefront of inhalation technology. Our comprehensive expertise spans the intricacies of formulation design, chemical manufacturing and controls (CMC) documentation, stability requirements, scale-up, comparative studies, and regulatory compliance. With a management team renowned for successfully navigating the Chlorofluorocarbon (CFC) to Hydrofluoroalkane (HFA) transition, OzUK is well-equipped to guide pharmaceutical professionals through the dynamic landscape of innovator product design, generic inhalation Metered Dose Inhalers (MDIs), and low-GWP propellant transition.
OzUK is not just a provider; we are your strategic partner in advancing inhalation innovation. Explore our wealth of experience, proven track record, and commitment to excellence as you embark on the next phase of inhalation product development with confidence and expertise.
Meet the Team
Paul Young
Robert Johnson
David Lewis
-
Chief Scientific Officer
Dr. David Lewis is an esteemed expert in Metered Dose Inhalers with over three decades of innovative experience in the pharmaceutical industry. Holding a B.Sc. in Physics and advanced degrees in Aerosol Science from Essex University, Dr. Lewis has pioneered advancements in inhalation technology, particularly in the development and reformulation of propellant technologies and metered dose inhaler products. Co-founder and Chief Scientific Officer of OzUK Laboratories, Dr. Lewis has been instrumental in driving the company's mission to deliver superior inhaler troubleshooting and development services globally. His work has led to the commercialization of numerous inhaler formulations across Europe, and he has authored over 175 research publications and holds more than 30 patents in the field. Dr. Lewis's leadership continues to position OzUK at the forefront of inhaler technology innovation.
-
Chief Operations Officer
Robert Johnson brings a wealth of expertise in pharmaceutical operations and drug development to his role as Chief Operations Officer at OzUK Laboratories. With a Bachelor’s Degree from Aberystwyth University, Robert has honed his skills in various critical roles across the industry. Before joining OzUK in February 2017, he worked with notable organizations such as PPD, Chiesi Group, Vectura Group plc., and AstraZeneca. His extensive experience includes the development and testing of pressurized metered dose inhalers, as well as pivotal work in formulation and packaging compatibility. Robert's leadership extends beyond the lab; he has been instrumental in setting up new research facilities and ensuring their operational excellence. At OzUK, he continues to drive the operational strategies that support the company’s innovative projects and global partnerships.
-
Chief Executive Officer
Professor Paul Young is a distinguished leader in the pharmaceutical and higher education sectors, with over 25 years of experience specializing in commercialization, entrepreneurship, and business creation. As the CEO of OzUK, he expertly guides innovations from conception to market, particularly focusing on metered dose inhalation products. Paul holds professorships in Commercialisation at Macquarie Business School and Respiratory Technology at the Woolcock Medical Research Institute, recognized globally for its respiratory and sleep disease research. Paul is CEO of Ab Initio Pharma, a cGMP manufacturing company and sits on the advisory boards of numerous pharmaceutical start-up companies. These positions underline his influential role in developing medical devices and therapeutics, leading to the creation of spin-off companies and significant pharmaceutical licensing deals. Professor Young’s career is marked by a dedication to mentorship and the strategic development of start-up ecosystems, particularly in the MedTech and Pharma sectors.
Location
OzUK is Headquartered in Chippenham, UK, along the M4 Corridor, Europe's premier business innovation and technology district, where it has two state-of-the-art R&D facilities for MDI and liquid aerosol research. Our facility can undertake early phase formulation and product discovery, Pharmacopeia testing, CMC package preparation for IND submission and regulatory support, small scale product manufacture, filling of both suspension and solution MDIs with novel gasses and propellants, full stability and compatibility services and on-site technology transfer, manufacturing plant set-up and production support.
